President Donald Trump announced a major agreement with pharmaceutical companies to lower U.S. prescription drug costs, a move the administration says aligns American prices with the lowest prices paid in other developed nations and aims to deliver significant savings for patients with chronic conditions.
President Donald Trump announced that his administration had brokered a deal to cut prescription drug costs to Americans on Friday, framing it as a historic victory for patients. He called the move “the great victory for patient affordability in the history of American healthcare by far,” and “the biggest thing to ever happen on drug pricing and on healthcare.”
Under the agreement, nine major pharmaceutical manufacturers signed on to measures designed to align U.S. prices with what other developed nations pay, a policy approach tied to the most-favored-nation, or MFN, principle. The administration emphasizes that matching those lower international prices will end the unfair burden American patients have carried for years while other countries paid less for the same medicines.
The deal targets deep discounts on drugs that treat chronic illnesses, with an explicit focus on conditions such as diabetes, arthritis, asthma, and certain cancers. Those categories include everyday medications millions of Americans depend on, so successful implementation could translate into meaningful out-of-pocket relief for families and seniors.
HHS Secretary Robert Kennedy Jr. endorsed the agreement at a White House briefing and highlighted the moral argument behind the move, arguing that the status quo was unsustainable. The announcement even drew praise from unexpected quarters, captured in the line that “this is the best achievement that could happen to our country.”
At the podium, the administration made clear that this was a negotiated outcome reached by persuading industry leaders to consider broader public health obligations. Those conversations, according to officials, involved showing CEOs the long-term logic of a price framework that keeps innovation viable while restoring fairness for American patients.
He continued, “I’m very grateful to all the CEOs who saw the sense in this, who understood the injustice and the unsustainability system, and who put public health, and particularly the public health of Americans, ahead of some of their other priorities. All of them came to the table.” This exact wording underscores the administration’s claim that industry leaders acted responsibly in response to the policy push.
The new agreement builds on the TrumpRx initiative and follows the May executive order, which the administration says set the stage for broad private-sector participation. According to the announcement, since that directive 14 of the 17 largest drug manufacturers globally have signed on to give Americans dramatically lower pricing, a show of cooperation the White House frames as historic.
Officials also pointed to a parallel HHS arrangement with the United Kingdom intended to shift the pricing balance overseas, noting that the deal “will increase the net price of new prescription drugs by 25% in the U.K., helping ensure they pay their fair share for innovative medicines,” according to the administration. That aspect is presented as part of a larger strategy to stop other nations from free riding on U.S. innovation.
The administration signaled more announcements are coming and suggested that additional companies, including Johnson & Johnson, are expected to finalize agreements soon. If that happens, the reach of the price adjustments would grow even wider, touching more therapies and more patients across the country.
For supporters, this package is proof that a pressure-and-negotiation approach can deliver practical results without upending the pharmaceutical ecosystem. The plan is positioned as a pragmatic step that lowers costs now while preserving incentives for future medical breakthroughs.
Editor’s Note: Thanks to President Trump’s leadership and bold policies, America’s economy is back on track.
